Jpmorgan Chase & CO Oric Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 35,649 shares of ORIC stock, worth $291,252. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,649
Previous 33,736
5.67%
Holding current value
$291,252
Previous $272,000
27.21%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ORIC
# of Institutions
144Shares Held
75.9MCall Options Held
11.3KPut Options Held
2.7K-
Viking Global Investors LP6.57MShares$53.7 Million0.12% of portfolio
-
Nextech Invest, Ltd. Zurich, V85.29MShares$43.2 Million6.85% of portfolio
-
Nextech Invest Ag5.29MShares$43.2 Million7.95% of portfolio
-
Black Rock Inc. New York, NY4.83MShares$39.5 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY4MShares$32.7 Million0.05% of portfolio
About Oric Pharmaceuticals, Inc.
- Ticker ORIC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,576,700
- Market Cap $323M
- Description
- ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...